Let's talk medical research

Last week, our team had the honor of attending the Mobile Pharma Summit, a gathering of technologically-inclined pharma movers and shakers interested in driving innovation through digital and mobile. Our Chief Development Officer, Tom Krohn, gave a talk with Pfizer’s ‎Head of New Clinical Paradigm, Munther Baara, on the ways that mobile drives Antidote’s capabilities. Drawing on the fact that 55% of Antidote's patient interactions and 88% of Antidote's Facebook engagement are on mobile, Tom highlighted the role of mobile in patient engagement and recruitment.

We talk a lot about the Cancer Moonshot and how our work dovetails with those efforts. Why is the Moonshot so important? One of the reasons is that beyond the obvious impacts, there are ripple effects that impact a variety of health communities – even those that are not directly involved.

Last week, we were honored to attend the Cancer Moonshot: One Year Later event in Washington, DC. This event was hosted by seven incredible advocacy organizations, and was a way for all who are working on Cancer Moonshot initiatives to provide an update on progress. You may recall that former Vice President Biden’s Cancer Moonshot project was an initiative meant to encourage collaboration and innovation in the cancer space in order to double the rate of progress in cancer in the next five years. As Greg Simon, former head of the Moonshot project and current president of the Biden Cancer Initiative, said, “the Moonshot is based on the notion that we can do anything - and the spirit of possibilities is contagious.” We agree.

One year ago today, JDRF launched Antidote Match on the Clinical Trials Connection page. To mark the occasion, our Director of Partnerships, Lindsey Wahlstrom-Edwards, sat down with our two main collaborators, Sydney Yovic, AVP of Research Operations and Mission, and Monica Harrington, Manager of Research Communications, to reflect on what we have learned over the last 12 months and to talk about next steps for the partnership.

One year ago, JDRF launched the Antidote Match tool on Clinical Trials Connection. In celebration of this anniversary, our Head of Partnerships, Grace McElroy, sat down with Dr. Aaron Kowalski, Chief Mission Officer, JDRF to discuss Type 1 diabetes and the importance of clinical trials.

More than 5 million people live with Alzheimer’s today. By 2050, that number could rise to as high as 16 million. Currently, there is not an effective treatment for Alzheimer’s symptoms or anything that slows or stops the disease. Researchers are also investigating what steps we can take to prevent the disease in the first place.

A few weeks ago, I wrote a blog post celebrating our partners and announcing that, in the coming weeks, we will be sharing their work more widely. It is my pleasure today to share our first partner feature: Lupus Research Alliance.

Today, we are pleased to announce a new partnership with the Lupus Research Alliance to help lupus patients and their loved ones find and understand their clinical trial options in a new way. Right now, there are more than 120 clinical studies in lupus, and they need more than 35,000 people to take part. It’s only by increasing the number of patients getting involved in research that we can expand lupus treatment options as we continue to drive discovery toward a cure.

Exactly one year ago, we launched Antidote Match, the first truly patient centric clinical trials search tool (see an example at the bottom of the post). Match aggregates and annotates all trials listed in clinicaltrials.gov to make it easy for people to connect with medical research regardless of their condition on the sites they already know and trust.

Will you be at DIA?